M&A - MCKESSON CORP
Form Type: 424B5
Filing Date: 2025-05-22
Corporate Action: Acquisition
Type: Update
Accession Number: 000162828025027266
Filing Summary: McKesson Corporation has filed a prospectus supplement to detail its offering of $2 billion in new notes, consisting of $650 million of 4.650% notes due 2030, $650 million of 4.950% notes due 2032, and $700 million of 5.250% notes due 2035. The proceeds are intended to finance the acquisition of a 70% stake in Community Oncology Revitalization Enterprise Ventures for approximately $2.49 billion. The prospectus includes details about the maturity dates, interest rates, and redemption options related to these notes. It also discusses the risks and factors involved in the investment, including the ranking of these notes as unsecured senior debt and covenants limiting future financial activities. Additionally, the offering's structure allows optional redemption and outlines the impact of change of control on the notes. Recent developments highlight another acquisition of an 80% interest in PRISM Vision Holdings for about $850 million and plans to separate the Medical-Surgical Solutions segment into an independent entity, although any such move is uncertain and dependent on external factors.
Additional details:
Note Type: 4.650% notes
Due Date 2030: May 30, 2030
Note Type 2032: 4.950% notes
Due Date 2032: May 30, 2032
Note Type 2035: 5.250% notes
Due Date 2035: May 30, 2035
Total Proceeds: $1,989,699,000
Use Of Proceeds: to fund acquisition of Core Ventures
Interest Payment Dates: May 30 and November 30, starting November 30, 2025
Risk Factors Section: Risk Factors starts on page S-8
Acquisition Details: Definitive agreement to acquire Core Ventures on August 26, 2024
Comments
No comments yet. Be the first to comment!